Morgan Stanley’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

Morgan Stanley’s Portfolio RSLS Stock Details RSLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1	Closed	–	–	6871
2018 Q3	$0	Sell	1 -1	-50%	-$86	﹤0.01%	6924
2018 Q2	$1K	Buy	2 +1	+100%	+$854	﹤0.01%	6637
2018 Q1	$2K	Sell	1 -1	-50%	-$3.18K	﹤0.01%	6516
2017 Q4	$5K	Buy	+2	New	+$6.62K	﹤0.01%	6351

Other funds holding RSLS

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Morgan Stanley's RSLS Position: Q4 2018 in Review

Morgan Stanley sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q4 2018, closing a stake of 1 share.

Morgan Stanley first reported a position in RSLS in Q4 2017 and held it in 4 quarters. The position peaked at $5K in Q4 2017. 2 funds tracked by Wall St. Rank hold RSLS as of Q4 2018.

Morgan Stanley reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Morgan Stanley sold 1 ReShape Lifesciences Inc. Common Stock share in Q4 2018.
Morgan Stanley first reported a position in ReShape Lifesciences Inc. Common Stock in Q4 2017 and held it in 4 quarters.
Morgan Stanley's ReShape Lifesciences Inc. Common Stock position peaked at $5K in Q4 2017.
2 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q4 2018.

Based on Morgan Stanley's 13F filing for Q4 2018, filed 14 Feb 2019.